Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/2/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
BofA/Merrill Lynch Starts Aimmune Therapeutics (AIMT) at Buy
August 31, 2015 7:43 AM EDTBofA/Merrill Lynch initiated coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Buy rating and a price target of $36.00.
For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.
Shares of Aimmune Therapeutics closed at $21.11 yesterday.
... MorePiper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight
August 31, 2015 6:27 AM EDTPiper Jaffray initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $35.00, leading data in peanut allergy.
Analyst Charles Duncan commented, "Aimmune is leveraging its broadly applicable oral immunotherapy (OIT) platform to develop proprietary products aimed at protecting patients... More
